Day: March 23, 2020

Press ReleaseOutside trading hours – Regulated information*Brussels, 23 March 2020, 7.15 a.m. CETKBC reaction to measures announced by Belgian Federal GovernmentThe global coronavirus pandemic presents the economy with complex challenges.Yesterday, the Belgian Federal Government, the National Bank of Belgium and Febelfin (the Belgian Banking Federation) have reached an agreement on the measures for banks in light of the Corona-crisis.The Royal Decree governing the implementation will be published after the vote on Thursday. The implementation by the financial sector can then start as of the end of this week.KBC Group is confident that, with strict and rigorous government action, the Belgian economy will be able to overcome the critical period.The economic impact of the corona-pandemic on the Belgian economy is still uncertain. As...

PersberichtBuiten beurstijd – Gereglementeerde informatie*Brussel, 23 maart 2020 – 7u15 uur CETKBC reactie op de maatregelen aangekondigd door de Belgische Federale regering De wereldwijde coronaviruspandemie stelt de economie voor complexe uitdagingen.Gisteren hebben de Belgische Federale regering, de Nationale Bank van België en Febelfin (de Belgische Bankenfederatie) een akkoord bereikt over de maatregelen voor de banken in het licht van de Corona-crisis.Het koninklijk besluit betreffende de uitvoering zal na de stemming van donderdag worden gepubliceerd. De uitvoering door de financiële sector kan dan vanaf het einde van deze week beginnen.KBC Groep heeft er alle vertrouwen in dat de Belgische economie, met een strikt en rigoureus overheidsoptreden, in staat zal zijn om de kritieke periode te boven te komen.De economische impact...

Communiqué de presseHors séance boursière – Information réglementée*Bruxelles, 23 mars 2020, 7h15 CET  Réaction de KBC aux mesures annoncées par le gouvernement fédéral belgeLa pandémie mondiale du coronavirus pose des défis complexes à l’économie.Hier, le gouvernement fédéral belge, la Banque nationale de Belgique et Febelfin (la Fédération des banques belges) sont parvenus à un accord sur les mesures à prendre par les banques à la lumière de la crise du coronavirus.L’arrêté royal régissant la mise en œuvre sera publié après le vote de jeudi. La mise en œuvre par le secteur financier pourra alors commencer dès la fin de cette semaine.KBC Groupe est convaincu qu’avec une action gouvernementale stricte et rigoureuse, l’économie belge sera en mesure de surmonter la période critique.L’impact économique de la...

23 March 2020 – Arcadis (EURONEXT: ARCAD), the leading global Design & Consultancy organization for natural and built assets, has repurchased 167,378 of its own shares in the period from 16 March 2020 up to and including 20 March 2020 at an average price of €13.26. This is in accordance with the repurchase in order to cover obligations from employee incentive plans and stock dividends as announced on Friday 6 March 2020. The consideration of this repurchase was € 2.2 million.The total number of shares repurchased under this program to date is 418,319 shares for a total consideration of €6.4 million.For more detailed information see: https://www.arcadis.com/en/global/investors/share-information/share-buyback-program/-End –For further information please contact:Arcadis Investor RelationsJurgen PullensMobile: +31 6 51599483E-mail:...

 Patient safety remains the top priority PRIMROSE 1 and PRIMROSE 2 trial results expected to be announced in Q2:20, as planned PROLONG trial results expected to be announced in 2H:20, as planned New patient screening and randomization in EDELWEISS 2 and EDELWEISS 3 trials on voluntary hold due to COVID-19 impact Current cash runway expected to fund operating expenses  into  3Q:21 GENEVA, Switzerland and BOSTON, MA (March 23, 2020) – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today provided an update regarding the impact of the COVID-19 pandemic on  its clinical development programs.“Our top priority is the safety of all the women who are participating in our clinical trials, as well as the health and safety of our employees...

WISeKey Releases CEO Letter to ShareholdersZug, Switzerland – WISeKey International Holding Ltd. (“WISeKey” NASDAQ: WKEY; SIX Swiss Exchange: WIHN), a leading cybersecurity and IoT company, today released a letter to shareholders from Carlos Moreira, WISeKey’s Founder and CEO.Dear Shareholders,The COVID-19 epidemic is affecting each of us and every business across the globe. Over the last three weeks, since the crisis started in Europe, we have taken initiatives to minimize risks to our business, develop and adapt new technologies to protect our customers against cyber-attacks and also protect shareholder value. Our senior management team’s experience during the 2000 and 2008 financial crises is proving to be very valuable and reassuring in dealing with the current epidemic crisis.WISeKey is fully operational and our staff is working...

Regulated informationRegulatory authorities approve JTA Phase III study in osteoarthritic knee pain and ALLOB Phase IIb study in difficult fracturesGosselies, Belgium, 23 March 2020, 7am CET – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases, today announces it has received regulatory approvals for its Clinical Trial Applications for the next studies of both of its lead candidates. These two studies are the pivotal JTA-004 Phase III clinical study targeting osteoarthritic knee pain and the Phase IIb study of its allogeneic cell therapy product, ALLOB, in patients with difficult tibial fractures. The JTA-004 trial has been approved by regulatory authorities in Denmark, and the ALLOB by Belgian regulatory authorities.Bone Therapeutics...

Information réglementéeApprobation par les autorités règlementaires de l’étude de Phase III évaluant JTA-004 dans la douleur liée à l’arthrose du genou et de l’étude de Phase IIb évaluant ALLOB dans les fractures difficilesGosselies, Belgique, le 23 mars 2020, 7h00 CET – BONE THERAPEUTICS (Euronext Bruxelles et Paris: BOTHE), société de biotechnologie spécialisée dans le développement de thérapies cellulaires et biologiques innovantes répondant à d’importants besoins médicaux non satisfaits dans les domaines de l’orthopédie et des maladies osseuses, annonce aujourd’hui avoir reçu des autorités règlementaires l’approbation de ses deux demandes d’essai clinique (CTA – Clinical Trial Application) pour le lancement des études cliniques de ses deux candidats médicaments principaux, à savoir l’étude pivotale de Phase III évaluant JTA-004 dans...

The list of AS LHV Group shareholders entitled to receive dividends will be established as at 27 March 2020 COB. Consequently, the day of change of the rights related to the shares (ex-dividend date) is set to 26 March 2020. From this day onwards, the person acquiring the shares will not have the right to receive dividends for the financial year 2019. Dividends shall be disbursed to the shareholders on 31 March 2020.Priit RumCommunication ManagerPhone: +372 502 0786Email: priit.rum@lhv.ee 

AS-i LHV Group dividendiõiguslike aktsionäride nimekiri fikseeritakse 27. märtsil 2020. aastal arveldussüsteemi tööpäeva lõpu seisuga. Sellest tulenevalt on aktsiatega seotud õiguste muutumise päev (ex-päev) 26. märts 2020. aastal. Alates sellest kuupäevast ei ole aktsiad omandanud isik õigustatud saama dividende 2019. aasta majandusaasta eest. Dividendid makstakse aktsionäridele 31. märtsil 2020. aastal.Priit RumLHV kommunikatsioonijuhtTelefon: 502 0786E-post: priit.rum@lhv.ee